(3R,4S)-methyl-1-benzyl-4-(tert-butoxycarbonyl)amino-pyrrolidine-3-carboxylate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (3R,4S)-methyl-1-benzyl-4-(tert-butoxycarbonyl)amino-pyrrolidine-3-carboxylate
• 英文别名: trans-Methyl 1-benzyl-4-((tert-butoxycarbonyl)amino)pyrrolidine-3-carboxylate；methyl (3R,4S)-1-benzyl-4-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidine-3-carboxylate
• 化学式: C₁₈H₂₆N₂O₄
• 分子量: 334.415
• InChiKey: MDCRPZPQWWVTKY-HUUCEWRRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  67.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3R,4S)-methyl-1-benzyl-4-(tert-butoxycarbonyl)amino-pyrrolidine-3-carboxylate 在 钯 氢气 、 甲醇 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 (3R*,4S*)-4-tert-Butoxycarbonylamino-pyrrolidine-3-carboxylic acid methyl ester
  参考文献：
  名称：

  Organic Compounds and Their Uses

  摘要：

  本申请描述了有机化合物，可用于治疗、预防和/或改善人类疾病。

  公开号：

  US20080045530A1
• 作为产物：
  描述：

  N-(甲氧甲基)-N-(三甲基硅甲基)苄胺 在 二苯基膦叠氮化物 、 三乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 反应 64.5h， 生成 (3R,4S)-methyl-1-benzyl-4-(tert-butoxycarbonyl)amino-pyrrolidine-3-carboxylate
  参考文献：
  名称：

  FUSED QUADRACYCLIC COMPOUNDS, COMPOSITIONS AND USES THEREOF

  摘要：

  本文提供了作为MK2抑制剂有用的替代融合四环化合物。本发明还提供了所述化合物的药物组合物。本发明还提供了替代融合四环化合物的医药用途。

  公开号：

  US20170190713A1

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET PROCÉDÉS POUR LEUR UTILISATION
  申请人：SPINIFEX PHARM PTY LTD

  公开号：WO2013102242A1

  公开（公告）日：2013-07-11

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及用于拮抗血管紧张素II型2（AT2）受体的杂环化合物。更具体地，本发明涉及吡咯烷和氮杂环丙烷化合物，含有它们的组合物以及它们在治疗或预防与AT2受体功能相关的疾病或疾病的方法中的使用，包括神经病性疼痛、炎症性疼痛、与神经元过敏、神经传导速度受损、细胞增殖紊乱、骨吸收和骨形成之间失衡以及与异常神经再生相关的疾病。
• Fused quadracyclic compounds, compositions and uses thereof
  申请人：Tabomedex Biosciences, LLC

  公开号：US10059718B2

  公开（公告）日：2018-08-28

  Provided herein are substituted fused quadracyclic compounds useful as inhibitors of MK2. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted fused quadracyclic compounds.

  本发明提供了可用作 MK2 抑制剂的取代融合四环化合物。本发明进一步提供了本发明化合物的药物组合物。本发明还提供了取代的融合四环化合物的医疗用途。
• Heterocyclic compounds and methods of their use
  申请人：NOVARTIS AG

  公开号：US10370388B2

  公开（公告）日：2019-08-06

  The present invention relates to heterocyclic compounds useful for antagonizing angiotensin II Type 2 (AT2) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.

  本发明涉及可用于拮抗血管紧张素 II 2 型（AT2）受体的杂环化合物。更具体地说，本发明涉及吡咯烷和氮杂环丁烷化合物、含有它们的组合物及其在治疗或预防与 AT2 受体功能有关的紊乱或疾病的方法中的用途，这些紊乱或疾病包括神经性疼痛、炎症性疼痛、与神经元超敏性有关的病症、神经传导速度受损、细胞增殖紊乱、与骨吸收和骨形成失衡有关的紊乱以及与神经再生异常有关的紊乱。
• HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE
  申请人：Novartis AG

  公开号：EP2800738B1

  公开（公告）日：2020-04-08
• Heterocyclic Compounds and Methods of Their Use
  申请人：Spinifex Pharmaceuticals Pty Ltd

  公开号：US20140378430A1

  公开（公告）日：2014-12-25

  The present invention relates to heterocyclic compounds useful for antagonising angiotensin II Type 2 (AT 2 ) receptor. More particularly the invention relates to pyrrolidine and azetidine compounds, compositions containing them and their use in methods of treating or preventing disorders or diseases associated with AT 2 receptor function including neuropathic pain, inflammatory pain, conditions associated with neuronal hypersensitivity, impaired nerve conduction velocity, cell proliferation disorders, disorders associated with an imbalance between bone resorption and bone formation and disorders associated with aberrant nerve regeneration.